Why the study?
Data on the efficacy and safety of therapeutic enoxaparin in obese patients needed systematic summarization to identify gaps and guide future research.
Does therapeutic enoxaparin dosing achieve safe and effective antifactor Xa levels, bleeding, and thrombotic outcomes in obese adults?
Does therapeutic enoxaparin dosing achieve safe and effective antifactor Xa levels, bleeding, and thrombotic outcomes in obese adults?
Due to substantial heterogeneity across existing studies, there is currently inadequate evidence to establish an optimal therapeutic enoxaparin dosing strategy in obese patients, though antifactor Xa monitoring may help guide dosing until further research is conducted.
Answers are grounded in this paper and cite their sources.
Enoxaparin dosing in obesity shows variable outcomes and lacks standardization; leaves open optimal regimens for prospective trials.
OBJECTIVE: This review aims to systematically summarize the available data on efficacy and safety of therapeutic enoxaparin in obese patients and to identify gaps to guide future research. DATA SOURCES: Medline and Embase were systematically searched for eligible studies (last searched December 20, 2023). Studies were included if they reported on therapeutic dosing regimens, adverse bleeding, thrombotic outcomes, or antifactor Xa (AFXa) monitoring in obese adult patients. STUDY SELECTION AND DATA EXTRACTION: The systematic review management tool Covidence was used to manage the study selection and data extraction process. The reference list from eligible studies was screened to determine any additional eligible studies. DATA SYNTHESIS: Sixteen studies were included in the analysis. Studies used a variety of doses, indications, and study designs making comparison difficult. Twelve studies reported the incidence of thrombotic events (median = 1.3% [interquartile range [IQR] = 0.3%-2.3%]) and all studies reported the incidence of bleeding events (median = 5.7% [IQR = 2.4%-14.5%]). Two of the 8 studies analyzing the influence of weight/body mass index (BMI) or dose per kg on AFXa levels reported statistically significant results. One study concluded that BMI did not affect achievement of target AFXa levels. However, the second study found that dosing using actual body weight was an independent predictor of supratherapeutic AFXa levels in the obese population. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: This is the first comprehensive review with a focus on therapeutic dosing of enoxaparin in obesity and has been conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Seven of the included studies were published since 2018 indicating that new evidence on this topic is emerging. CONCLUSION: There was inadequate evidence to support an optimal dosing strategy in obese patients due to the heterogeneity of the studies. The AFXa monitoring may be appropriate to guide dosing in this population. Further research is required to determine a suitable dosing regimen.
No takes yet. Share an insight, caveat, or question.
Appay et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: